NeuroPace, Inc. (NPCE)
Largest Insider Buys in Sector
NPCE Stock Price History Chart
NPCE Stock Performance
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was …
Insider Activity of NeuroPace, Inc.
Over the last 12 months, insiders at NeuroPace, Inc. have bought $0 and sold $11.47M worth of NeuroPace, Inc. stock.
On average, over the past 5 years, insiders at NeuroPace, Inc. have bought $12.85M and sold $3.86M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 62,398 shares for transaction amount of $93,535 was made by Accelmed Partners II L.P. (director) on 2022‑11‑22.
List of Insider Buy and Sell Transactions, NeuroPace, Inc.
| 2024-10-25 | Sale | 10 percent owner | 223,991 0.697% | $5.45 | $1.22M | 0.00% | ||
| 2024-10-23 | Sale | 10 percent owner | 147 0.0005% | $6.02 | $885 | 0.00% | ||
| 2024-10-22 | Sale | 10 percent owner | 4,082 0.0142% | $6.09 | $24,853 | 0.00% | ||
| 2024-10-21 | Sale | 10 percent owner | 3,720 0.0125% | $6.10 | $22,679 | +4.03% | ||
| 2024-10-18 | Sale | 10 percent owner | 4,878 0.0162% | $6.29 | $30,692 | -0.93% | ||
| 2024-10-17 | Sale | 10 percent owner | 3,294 0.0111% | $6.28 | $20,686 | +0.94% | ||
| 2024-10-16 | Sale | 10 percent owner | 6,900 0.0231% | $6.57 | $45,336 | -0.31% | ||
| 2024-10-15 | Sale | 10 percent owner | 4,017 0.0133% | $6.50 | $26,098 | -0.31% | ||
| 2024-10-14 | Sale | 10 percent owner | 4,031 0.0134% | $6.54 | $26,360 | -0.23% | ||
| 2024-10-11 | Sale | 10 percent owner | 2,572 0.0083% | $6.35 | $16,320 | -2.42% | ||
| 2024-10-10 | Sale | 10 percent owner | 2,504 0.0078% | $6.12 | $15,317 | +3.95% | ||
| 2024-10-09 | Sale | 10 percent owner | 3,123 0.0097% | $6.10 | $19,065 | +5.56% | ||
| 2024-10-08 | Sale | 10 percent owner | 6,000 0.0196% | $6.43 | $38,552 | +0.39% | ||
| 2024-10-07 | Sale | 10 percent owner | 4,910 0.0167% | $6.66 | $32,687 | -3.59% | ||
| 2024-10-04 | Sale | 10 percent owner | 5,757 0.0203% | $6.92 | $39,830 | -5.64% | ||
| 2024-10-03 | Sale | 10 percent owner | 3,318 0.0118% | $6.97 | $23,115 | -7.19% | ||
| 2024-10-02 | Sale | 10 percent owner | 3,843 0.0135% | $6.87 | $26,401 | -6.85% | ||
| 2024-10-01 | Sale | 10 percent owner | 4,882 0.0168% | $6.77 | $33,051 | -6.10% | ||
| 2024-09-30 | Sale | 10 percent owner | 4,749 0.0163% | $6.73 | $31,961 | -7.32% | ||
| 2024-09-27 | Sale | 10 percent owner | 5,059 0.0171% | $6.63 | $33,541 | -3.29% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 10 percent owner | 3406335 11.6667% | $7.78 | 1 | 14 | |
| Accelmed Partners II L.P. | director | 4432948 15.1829% | $7.78 | 3 | 0 | +199.33% |
| Norton Evan | director | 588235 2.0147% | $7.78 | 1 | 0 | |
| Fischer Frank M | director | 93291 0.3195% | $7.78 | 1 | 0 | |
| Ridley Irina | General Counsel and Secretary | 61139 0.2094% | $7.78 | 1 | 2 |
Institutional Investor Ownership
| OrbiMed | $52.85M | 13.92 | 4M | 0% | +$0 | 0.41 | |
| Morgan Stanley | $32.79M | 8.63 | 2.48M | +0.95% | +$307,124.40 | <0.01 | |
| Soleus Capital Management, L.P. | $32.12M | 8.46 | 2.43M | 0% | +$0 | 0.13 | |
| Nantahala Capital Management Llc | $10.27M | 2.71 | 778,260 | -33.69% | -$5.22M | 0.48 | |
| Kent Lake Capital LLC | $8.5M | 2.24 | 643,629 | -4.07% | -$360,584.41 | 3.84 |